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Transplantation has significantly advanced in the past 30 years. The availability of 
T -cell-directed immunosuppressive agents (FK506, Rapamycin, Cyclosporine. 
Azathioprine) has allowed pancreatic transplantation to become an accepted therapeutic 
approach for treatment of diabetes. In recent years, the development of procedures to 
isolate large numbers of pancreatic islets has made it possible to initiate clinical trials 
for cellular replacement of pancreatic endocrine function. l -6 Transplantation of pancre-
atic islets is the most focused approach to treat diabet~ and may offer a number of 
advantages over transplantation of the whole pancreas as 0\ primarily vascularized graft. 
In addition to the potential for cryopreservation and islet "banking", in vitro pretreat-
ment of free cellular grafts is more feasible than with solid organs. Finally, one can 
eliminate the requirement for vascular and ductal anastomoses which must accompany 
the transplantation of solid pancreas grafts. 
It is well recognized that all pancreas grafts are highly antigenic. 1-8 Although one 
might predict that free cellular grafts would be less antigenic than a primarily 
vascularized solid organ graft, the opposite has proven to be true.1.8 CellulaI grafts are 
even more antigenic than the whole pancreas if one uses rejection-free survival and 
function as the criteria for judging graft immunogeniciry. Approaches to reduce 
immunogenicity of the islet grafts, including graft pretreatment with monoclonal 
antibodyIT·~·9-11 in vitro culture techniques,4.10-12 ultraviolet irradiation of the grafts, 14-16 
microencapsulation,l7-20 and isolation of hand-picked B-cells21 .22 have resulted in 
prolonged graft survival, bur these approaches have not reliably prevented graft 
rejection. The induction of donor-specific transplantation tolerance across MHC 
disparities, or even species barriers. has been suggested as a potential approach to 
overcome the limitation of graft rejection. To date, the only state of true systemic donor-
specific transplantation tolerance has been that associated with chimerism, the engraft-
ment ofbone marrow stem cells in a conditioned recipient. The association of chimerism 
and tolerance will be the focus of this chapter. 
The recognition that bone marrow stem cells possess a unique property to induce 
systemic and permanent transplantation tolerance to donor histocompatibility antigens 
was made in the late 1940s and early 1950s. Owen detected mixed red blood cell 
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chimerism in fraternal twins which shared a 
common placenta (freemartin cattle) and con-
cluded that this was possible only ifhematopoi-
etic stem cells had been exchanged in utero.23 
This effect persisted in these animals throughout 
their lifespan. The implications of this phenom-
enon for transplantation immunology would 
prove to be profound: if donor bone marrow cells 
could be engrafted in normal recipients, they 
would not be rejected, but instead would persist 
in a mutual state of cotolerance. 
Contemporaneously, Billingham, Brent and 
Medawar became aware of Owen's observation 
when they were asked by the Agricultural Re-
search Council to develop a model to distinguish 
monozygotic from dizygotic cattle twins. It was 
important to the cattle industry because "free-
martin" (chimeric) cattle were virtually always 
sterile and therefore not economical to raise. 
Billingham, Brent and Medawar had developed 
a method to use skin grafting to perform histo-
compatibility typing. They had demonstrated 
skin graft rejection in the presence ofhistocom-
patibiliry differences. However, to their surprise 
they found that dizygotic freemartin cattle ac-
cepted skin grafts from their sibling just as 
readily as did monozygotic (identical) twins, The 
presence of donor chimerism had rendered the 
recipients tolerant. They immediately attempted 
to transfer bone marrow cells into newborn mice 
to determine whether donor-specific skin graft 
survival could be achieved. This led to the report 
of "actively acquired tolerance offoreign cells" in 
which transplantation of Major Histocompat-
ibility Complex (MHC)-disparate bone mar-
row stem cells into neonatal recipient mice induced 
specific and systemic tolerance to the donor with 
preservation of immunocompetence to reject 
genetically different third parry grafts from other 
donors. 24 Moreover,the tolerance was stable and 
persisted into the adult life of the recipient. 
The fetus and newborn possess a privileged 
state in which no conditioning is required to 
achieve engraftment of bone marrow cells in the 
form of chimerism. In the mouse, this stem cell 
engraftment can be achieved until 72 hours after 
birth. In the human fetus, this occurs until 16 
weeks of gestation. After that, approaches to 
condition the recipient or "make space" to allow 
bone marrow stem cells to engraft must be 
utilized (conditioning). 
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After the pioneering work of Billingham et 
al in neonatal mice, approaches to achieve similar 
chimerism in adult recipients were reported. 
Conditioning approaches to allow engraftment 
of donor stem cells included total body irradia-
tion,25,26 total lymphoid irradiation,27 and 
pharmacologic cytoreductive approaches, i.e., 
cyclophosphamide.28 With each of these ap-
proaches, donor-specific transplantation toler-
ance to subsequent solid organ or tissue grafts of 
donor-type was achieved. The tolerance induced 
was stable, systemic, and specific for the donor. It 
did not require the use of chronic nonspecific 
immunosuppressive agents. Hence the recogni-
tion that chimerism was associated with toler-
ance for tissue and solid organ grafts. 
It is now well accepted that full replacement 
of the immune system of the recipient with that 
of donor (fully allogeneic chimerism) results in 
systemic donor-specific transplantation tolerance. 
However, this state is complicated by a relative 
state of recipient immunoincompetence.29-31 The do-
nor T-Iymphocyres which develop in the recipi-
ent are restricted to interacting with 
antigen-presenting cells (APC) of the host. With 
full replacement of all bone-marrow-derived cells, 
only donor APCs are present. As a result, primary 
immune responses which rely on APCs, includ-
ing antibody production,32 antiviral responses,30 
and survival are significantly impaired, result-
ing in a state of relative recipient 
immunoincompetence.33 Therefore, tolerance 
and immunocompetence are two independent 
variables. 
The presence of syngeneic bone marrow cells 
in coexistence with allogeneic bone marrow (mixed 
chimerism) results in similar systemic donor-spe-
cific transplantation tolerance for solid organ 
grafts with the advantage that recipient immu-
nocompetence is preserved. The appropriate host-
derived APCs are present and a state of mutual 
cotolerance is induced. The donor and host bone 
marrow stem cells co-engraft and function to 
produce multilineage mixed chimerism. A mix-
ture of donor and recipient red blood cells, plate-
lets, B-cells, T -cells, NK cells, macrophages and 
other APCs, granulocytes and monocytes can be 
detected (manuscript submitted). In striking 
contrast to fully allogeneic chimeras, mixed allo-
geneic chimeras exhibit superior immunocom-
petence for antibody production, antiviral 
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responses, and survival.31 -B Most importantly, a 
relative resistance to graft versus host (GVH) 
disease is present in mixed allogeneic chimeras 
due to mechanisms which have not yet been 
elucidated.25.26.31.32 Similar resistance to GVH 
disease has been reported in human recipients of 
allogeneic bone marrow who by chance reconsti-
tuted as mixed chimeras. 34 
Mixed chimerism can be achieved by 
coadministration of syngeneic plus allogeneic 
bone marrow following conditioning with total 
body irradiation (TBI),J2 transplantation of 
untreated allogeneic bone marrow following to-
tal lymphoid irradiation (YU),27 or following 
administration of untreated (T-replete) bone 
marrow in conjunction with low-dose irradiation 
plus cydophosphamide28 or monoclonal ami-
body.J5 In each of these widely different ap-
proaches, the induction of donor-specific 
transplantation tolerance plus resistance to GVH 
disease was observed, reinforcing the strong asso-
ciation of tolerance with chimerism. Most im-
portantly, the presence of chimerism, no matter 
how low the level, conferred stable systemic 
donor-specific transplantation tolerance. The 
tolerance induced was not incremental, but rather 
an all-or-none effect. 
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The transplantation of bone marrow cells 
across xenogeneic barriers has been demonstrated 
to produce bone marrow rescue following lethal 
irradiation.16-39 As in allogeneic chimeras, the 
presence of xenogeneic chimerism is associated 
with the induction of donor-specific transplanta-
tion tolerance to solid organ or tissue grafts. 39-41 
Until recently, xenogeneic chimerism was lim-
ited by transient engraftment of the donor bone 
marrow cells and inferior recipient survival.J9-41 
It has now been reported that the administration 
of 40 x 106 untreated rat bone marrow cells into 
B 1 0 mouse recipients conditioned with 950 rads 
ofTBI (rat - mouse) (Fig. 1) resulted in stable 
fully xenogeneic chimerism, excellent survival, 
resistance to GVH disease, and the induction of 
stable donor-specific transplantation toleranceY 
Rat T-cell maturation proceeded in a phenotypi-
cally normal fashion in the chimeric mouse re-
cipients, as evidenced by an immature-staining 
profile by flow cytometry in the thymus and 
mature profile in the periphety (Fig. 2). Most 
importantly, the rat-derived lymphocytes were 
functionally tolerant to both recipient mouse and 
donor rat antigens, yet fully-reactive to MHC-
disparate third party mouse and rat antigens 
indicating that mouse and rat are not seen as 
generic species but instead in an MHC-strain-
~K 
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specific fashion when tolerance is induced across 
a species barrier12 (manuscript in preparation). 
Mixed xenogeneic chimeras (mouse + rat-
mouse) have been prepared by coadministering 
T-cell-depleted syngeneic mouse plus untreated 
rat bone marrow to mouse recipients conditioned 
byTBI(Fig. 3 ).43 Stable xenogeneic multilineage 
chimerism ranging from 1 % to 56% rat for 
individual recipients has been demonstrated. As 
in mixed allogeneic chimeras, any level of detect -
able xenogeneic chimerism was associated with 
stable, systemic donor-specific transplantation 
tolerance in vivo and in vitro. Most importantly, 
mixed xenogeneic chimeras exhibited superior 
immunocompetence, probably for reasons simi-
lar to those observed in mixed allogeneic chime-
ras. Although untreated rat bone marrow cells are 
administered, there is no evidence for GVH, 
suggesting that there is a resistance to GVH 
across a species barrier. Mixed xenogeneic chime-
ras accept donor-specific skin grafts, but reject 
MHC-disparate third party mouse and rat skin 
grafts with atimecoursesimilar to unmanipulated 
mice.<13 
Although significant progress has occurred 
in transplantation in the past 30 years, twO major 
limitations exist: (1) there is a critical shortage of 
allogeneic donors; and (2) rejection occurs in 
spite of conventional multimodal immunosup-
pression. These limitations are especially true for 
cellular grafts. The induction of donor-specific 
transplantation tolerance across species dispari-
ties has been suggested as a potential approach to 
overcome these limitations. 
Recently, fully xenogeneic chimerism was 
applied to induce tolerance for pancreatic islet 
xenografts. Permanent, rejection-free graft sur-
vival (> 9 months) was demonstrated when 
nonhandpicked pancreatic islet xenografts were 
transplanted in fully xenogeneic (rat - mouse) 
chimeras. 12 In this experiment, chimeras were 
prepared and typed for chimerism at 6 weeks 
(Fig. 4). Diabetes was then induced using a single 
dose of intravenous streptozotocin (165 mg/kg). 
After 5 to 7 days of documented hyperglycemia 
(blood glucose > 300 mg/dl), either a donor-
specific or MHC-disparate third party islet xe-
nograft placed under the renal capsule. 
MHC-disparate third party grafts were rapidly 
rejected (median survival time = 9 days) in a time 
course similar to unmanipulated B 1 0 mice while 
donor-specific islet grafts were permanently ac-
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cepted (Fig. 5). To document that glucose ho-
meostasis was maintained by the islet xenografts 
and was not due to regeneration of function in the 
native pancreatic endocrine tissue, transplant 
nephrectomy was performed at selected time 
points (Fig. 6). In all recipients analyzed from 90-
270 days (n=8),hyperglycemiarecurred, thereby 
confirming functional integrity of the islet xe-
nografts (Fig. 7). The islet grafts and native 
pancreas were examined immunohistochemically 
using immunoperoxidase stains to detect insulin 
prcxiuction. Normal appearing pancreatic islet 
tissue positive for insulin prcxiuction was present, 
supporting functional integrity of thexenografts. 
No evidence for mononuclear cell infiltrates 
could be detected. As expected, the native pan-
creas had no evidence for insulin prcxiuction, 
confirming that glucose homeostasis was indeed 
maintained by the islet xenografts. Similar long-
term rejection-free graft survival and normal 
function of donor-specific islet xenografts has 
been achieved in mixed xenogeneic chimeras 
(mouse + rat - mouse).44 Hence, this approach 
for tolerance induction has proven effective to 
allow permanent survival and function of islet 
grafts. 
Pancreatic Islet Cell Transplantation 
It has become apparent that although T-
cell-ditected antirejection therapy has made a 
significant improvement in graft survival, per-
manent rejection-free graft survival has nor yet 
been achieved. Agents directed at other media-
tors in the complex rejection pathway, i.e., 
cytokines, antigen-presenting cells, or B-lym-
phocytes, in combination with T-cell directed 
immunosuppressive agents (FK506, cyclosporine 
A, Rapamycin) may offer the optimal combina-
tion to achieve permanent rejection-free graft 
survival. If not, the use of one cellular graft (bone 
marrow) to induce tolerance to strain and even 
species disparities may provide an approach to 
achieve permanent, rejection-free survival of other 
cellular grafts, i.e., pancreatic islets. 
The transplantation of bone marrow cells to 
treat malignancy, stem cell failure, and genetic 
defects represents the first successful clinical 
application of cellular transplantation.-l7 After 
the demonstration that rescue from lethal irra-
diation could be achieved using the intravenous 
injection of bone marrow cells, evidence accumu-
lated that the "barrier" to transplantation previ-
ously described by Alexis Carrel, may in fact not 
be totally impenetrable. The neonatal chimerism 
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documented in Medawar's experiments gave fur-
ther support to the paradigm that the histocom-
patibility bartierto transplantation was not totally 
insurmountable. The pioneering work of Dr. E. 
Donnall Thomas and colleagues applied these 
observations to the transplantation of cellular 
bone marrow grafts for treatment of hematologic 
malignancy and the field of bone marrow trans-
plantation became a clinical reality.48 
Although bone marrow transplantation de-
veloped in parallel and sometimes divergent 
pathway from solid organ transplantation, a re-
cent mutual recognition has led to a merging of 
these two areas so that the lessons of each can be 
shared by both. In this way, it is quite appropriate 
to speculate that the use of one cellular graft, i.e. 
bone marrow, might be applied to achieve per-
manent survival of a second cellular graft, i.e., 
pancreatic islets. 
The clinical application of bone marrow to 
prolong survival of solid organ allografts has 
begun. In a recent report, two patients who 
receivedHLA-matchedliving-relateddonorbone 
marrow grafts for hematologic malignancy de-
veloped renal failure as a late complication of 
their chemotherapy.4) Both were given a renal 
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allograft from the same bone marrow donor and 
have experienced rejection-free graft survival 
without immunosuppression. In pioneering stud-
ies, Barber et al reported prolongation of renal 
allograft survival when cadaver donor bone mar-
row was administered 10 days following place-
ment of the renal graft in conjunction with low 
dose cyclophosphamide. 46 A significant improve-
ment in graft survival was observed and most 
importantly, no significant morbidity, i.e., GVH, 
was observed when T-cell replete donor bone 
marrow cells were administered. 
ACKNOWLEDGEMENTS 
The authors thank Michelle Waters for sec-
retarial support, Richard James and Kathie Carr 
for technical support, and Drs. Christina Kaufman 
and Ashraf Abou El-Ezz for manuscript review. 
REFERENCES 
I. Aledandro R, Mintz 0, Noel J et at. Islet cell 
transplantation in type I diabetes mellitus. 
Transplant Proc 1987; 19:2359. 
2. Warnock J. Studies of the isolation and viability of 
human Islets of langerhans. Transplant 1988; 
45:957. 
3. Ricordi C, Lacy PE, Finke EH et al. Automated 
method for isolation of human pancreatic islets. 
Diabetes 1988; 37:413. 
4. Sharp OW, Lacy PE, Ricordi C et al. Human islet 
transplantation in patients wi th type I diabetes. 
Transplant Proc 1989; 21:2744. 
5. Warnock GL, Kneteman NM, Ryan EA et al. 
Continuous function of pancreatic islet after 
transplantation in type I diabetes. Lancet 1989; 
2:570. 
6. Tzakis AG. Ricordi C, Alejandro R et al. Pancreatic 
islets transplantation after upper abdominal 
exenteration and liver replacement. Lancet 1990; 
18:402. 
7. Faustman 0, Hauptfeld V, Davie JM, Lacy PE. 
Prolongation of murine islet allograft survival by 
pretreatment of islets with antibody directed to Ia 
determinants. Proc Nat! Acad Sci (USA) 1981; 
78:5156. 
8. Steinman RM, Witmer MD. Lymphoid dendritic 
cells are potent stimulators of the primary mixed 
leukocyte reaction in mice. Proc Nat! Acad Sci 
(USA) 1978; 75:5132. 
9. Faustman 0, Steinman RM, Geble HM et al. 
Prevention of rejection of murine islet allografts 
by pretreatment with antidendritic cell antibody. 
Proc Nat! Acad Sci (USA) 1984; 81:3864. 
10. Lacy PE, Davie JM, Finke EH. Prolongation of 
islet allograft survival following in vireo culture 
(24C) and single injection of ALS. Science 1979; 
204:312. 
Pancreas Procurement and Preservation: Impact on Islet Recovery and Viability 175 
Ii. Faustman D. Lacy PE, David )M, Haupctdd V. 
Prevention of allograft rejection by immunization 
with donor blood depleted of Ia-bearmg cells. 
Science 1982; 217: 157. 
12. Bowen KM. Andrus L, Lafferry KJ. Successful 
allotransplantation of mouse pancreatic islets to 
nonimmunosuppressed recipients. Diabetes 1980; 
29:98. 
13. Barker CF, Naji A, Silvers WK. Immunological 
problems in islet transplantation. Diabetes 1980 
(Supple 2); 29:86. 
14. Naji A, Silver WK, Barker CF. Successful islet 
transplantation in spontaneous diabetes. Surgery 
1978; 86:218. 
15. uu H, Reemtsma K, Hardy MA. Pancreatic islet 
allograft prolongation by donor-specific blood 
transfuSIOn treated with ultraviolet irradiation. 
Science 1983: 221 :754. 
16. uu H. Reemtsma K, Hardy MA. The use of direct 
ultraViolet irradiation and cyclosporine In 
facili tating indefinite pancreatic islet graft 
acceptance. Transplant 1984; 38:566. 
17. Lim F, Sun AM. Microencapsulated islet as 
bioartificial endocrine pancreas. Science 1980; 
210:908. 
18. Goosen MFA, O'Shea GM, Gharapetian HM e al. 
Optimization of microencapsulation parameters: 
semi-permeable microsules as bioarriticial pancreas. 
Biotechnol Bioeng 1985; 27:146. 
19 O'SheaGM, Sun AM. Encapsulation of rat islets of 
ungerhans prolongs xenograft in diabetic mice. 
Diabetes 1986; 35: 943 . 
20. Norton )E, Weber CJ, Reemtsma K. 
Microencapsulation . Transplantation of the 
Endocrine Pancreas in Diabetes Mellitus. 1988; 
308. 
21. Gotoh M. Maki T, Satomi S et al. Immunological 
characteristicS of purified pancreatic islet grafts. 
Transplant 1986; 42:387. 
22. GotohM,Kaoai T,PorrerTetai. Use of composite 
and sequential islet allografts for cure of 
experimental diabetes: a porential protocol for 
clinical application. Transplantation of the 
Endocrine Pancreas in Diabetes Mellitus. 1988; 
pp 315-318. 
23. Owen RD . Immunologic consequences of vascular 
anastomoses between bovine twins. Science 1945; 
102:400. 
24. Billingham RE, Brent L, Medawar PB. Actively 
acquired tolerance of foreign cells. Nature 1953; 
172: 603. 
25. Ildstad ST, Sachs DH. Reconstitution with 
syngeneic plus allogeneic or xenogeneic bone 
marrow leads to specific acceptance of allografts or 
xenografts. Nature 1984; 307:168. 
26. Ildstad ST, Wren SM, Bluestone )A et al. 
Characterization of mixed allogeneic chimeras: 
Immunocompetence in vitro reactiviry and genetic 
specificiryoftolerance.) ExpMed 1985; 162:231. 
27. Slavin 5, Fuks Z, Kaplan HS, Serober 5. 
Transplantation of allogeneic bone marrow without 
graft versus hose disease using total lymphoid 
irradiation.) ExpMed 1978; 147:963. 
28. Mayumi H, Good RA. Long-lasting skin allograft 
tolerance in adult mice induced across a fully 
allogeneic antigen barriers by a tolerance-inducing 
method using cyclophosphamide. ) Exp Med 
1989; 160:213. 
29. Rayfield LS, Brene 1. Tolerance, 
immunocompetence, and secondary disease in 
fully allogeneic radiation chimeras. Transplant 
1983; 36:183. 
30. Singer A, Hathcock KS, Hodes R). Self recognition 
in allogeneic radiation bone marrow chimeras: A 
radiation-resistant host element dictates the self-
specificity and immune response gene phenotype 
of T-helper cells. J Exp Med 1981; 153: 1286. 
31. Ruedi E,SykesM,IldstadSTetal. Antiviral T-cell 
competence and restriction specificity of mixed 
allogeneic (PI + P2-+Pll irradiation chimeras. 
Cellular Immunology 1989; 121: 185. 
32. Ildstad ST, Wren SM, Barbieri SA, Sachs DH. 
Characterization of mixed allogeneic chimeras: 
Immunocompetence, in vitro reactivity, and 
genetic specificity of tolerance.) Exp Med 1985; 
162:231. 
33. Sykes M, Sachs DH. Mixed allogeneic chimerism 
as an approach to transplantation tolerance. 
Immunology Today 1988; 9:23. 
34. Hill RS, Peterson FB, Storb R et ai. Mixed 
hematologic chimeras after allogeneic marrow 
transplant for severe aplastic anemia is associated 
with a higher risk of graft rejection and a lessened 
incidence of acute graft-versus-host disease. Blood 
1986; 67:811. 
35. Sharabi Y, Sachs DH. Mixed chimerism and 
permanent specific transplantation tolerance 
induced by a nonlethal preparative regimen.] Exp 
Med 1989; 169:493. 
36. Congdon CG, Lorenz E. Humoral factor in 
irradiation protection: modification of lethal 
irradiation injury in mice by injection of rat bone 
marrow. Am J Physiology 1954; 176:297. 
37. Nowell PC, Cole LH, Habermeyer )G, Roan Pi. 
Growth and function of rat marrow cells in x-
irradiated mice. Cancer Res 1955; 16:258. 
38. Ford CE, Hamerron )L, Barnes DW, Loutit )F. 
Cytological identification of radiation chimeras. 
Nature (London) 1956; 177:452. 
39. ZaalbergOB, VosO, Van Bekkum DW. Surviving 
rat skin grafts in mice. Nature (London) 1957; 
80:238 
40. Ildstad ST, Wren SM, Sachs DH. In vivo and in 
Vitro characterization of specific hyporeactivity to 
skin xenografes 10 mixed xenogeneically 
reconstituted mice(BI0 + F344 rat-+BlO).) Exp 
Med 1984; 160:1825. 
41. Auchincloss H. Xenogeneic transplantation. 
Transplantation 1988; 46: 1. 
42. Ildstad ST, Wren SM, Boggs SS, Hronakes ML et 
al. Cross-species bone marrow transplantation: 
Evidence for tolerance induction, stern cell 
176 
engraftmenr, and maturation ofT -lymphocytes in 
a xenogeneic stromal environmenr (rat Ii mouse). 
] ExpMed 1991; 174:467. 
43. lIdstad ST, Boggs SS, Vecchini F et al. Mixed 
xenogeneic chimeras (rat + mouse-+rat): Evidence 
for rat stem cell engraftmenc, strain-specific 
transplantation tolerance, and skin-specific 
anrigens. Transplantation 1992; In press. 
44. Zeng Y, Ricordi e, Tzakis A et al. Long term 
survival of donor-specific pancreatic islet xenografts 
in fully xenogeneic chimeras (WF rat Ii BI0 
mouse). Transplantarion 1992; In press. 
45. SayeghMH,FineNA,SmithJLetal.Immunologic 
tolerance to renal allografts after bone marrow 
transplants from the same donors. Annals of 
Pancreatic Islet Cell Transplantation 
Internal Med 1991; 114:954. 
46. Barber WH, Mankin JA, Laskow DA et al. Long 
term resultS of a controlled prospective study with 
transfusion of donor-specific bone marrow in 57 
cadaveric renal allograft recipientS. Transplantation 
1991; 51:70. 
47. Thomas ED, Lochte HL, Lu we, Ferrebe ]W. 
Intravenous infusion of bone marrow in patients 
receiving radiation and chemotherapy. N Eng J 
Med 1957; 257:491. 
48. Thomas ED. Allogeneic marrow grafting _ a 
story of man and dog. In: Terasaki P, ed. History 
of Transplantation: Thirty-Five Recollections. 
1991: 380-390. 
